GH Research
GH Research

GH Research

Pharmaceuticals
WebsiteInvestor RelationsSEC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

$1.6B

Market Cap • 10/2/2026

2021

(5 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Ireland

Ireland

Country

Valuation

P/B

4,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

5,2

EPS

—

Market Cap

Market Cap

1,6B

EV

1,2B

EV/Revenue

0

EV/EBITDA

-17

EV/EBIT

-17

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-16%

Total Yield

-16%

Payout

0%

Retained Earnings

-187,8M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

38,4%

Capex/OCF

-0,3%

SBC/OCF

—

% PPE

0,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

76,3%

CAGR Net Income 5Y

76,3%

CAGR EPS 5Y

56,4%

CAGR OCF 5Y

91,8%

Leverage

N.D./EBITDA

5,1

Debt/Equity

0%

Current Ratio

28,7

Quick Ratio

28,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium